Apogee's Zumilokibart Shows Durable Efficacy in Atopic Dermatitis Phase 2 Trial
Event summary
- Apogee Therapeutics' Phase 2 Part A trial of Zumilokibart (APG777) demonstrated durable maintenance of response at 52 weeks with 3- and 6-month dosing regimens.
- 75% and 85% of patients maintained EASI-75 with 3- and 6-month dosing, respectively, while 86% and 78% maintained vIGA 0/1.
- Deepening of response was observed across all lesional and itch endpoints with both dosing regimens.
- APEX Part B 16-week induction data expected in 2Q 2026, with Phase 3 trials planned for 2H 2026.
The big picture
Apogee's positive Phase 2 data for Zumilokibart positions the company to challenge existing treatments for moderate-to-severe atopic dermatitis with a potentially best-in-class profile. The durable efficacy and deepening of response observed with less frequent dosing could reshape the treatment paradigm, addressing a significant unmet need for patients seeking long-term disease control with fewer injections. The upcoming Phase 3 trials will be critical in validating Zumilokibart's commercial potential in one of the largest and least penetrated immunology markets.
What we're watching
- Regulatory Pathway
- Whether the Phase 2 data will support a smooth transition to Phase 3 trials and potential commercial launch in 2029.
- Competitive Positioning
- How Apogee's less frequent dosing regimen will differentiate Zumilokibart in the crowded atopic dermatitis market.
- Pipeline Expansion
- The pace at which Apogee will expand Zumilokibart into other inflammatory and immunology indications like asthma and EoE.
Related topics